CONTINUE TO SITE

OR WAIT null SECS

Carl Zeiss Case Studies High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma iCare COMPASS Automated Perimeter

Carl Zeiss Case Studies High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma iCare COMPASS Automated Perimeter

View More Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Medical World News

Eyeviews Medical World News Podcasts Rapid Readouts Viewpoints

Digital Edition

Supplements And Featured Publications

Digital Edition Supplements And Featured Publications

Conference Coverage

Conference Listing

Sponsored Resources

Zeiss Case Studies

Sponsored Resources Zeiss Case Studies

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2022 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Carl Zeiss Case Studies
High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma
iCare COMPASS Automated Perimeter

ClinicalSee All >

Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2022 MJH Life Sciences^™ and Opthalmology Times Europe. All rights reserved.

New therapy enters trials

July 8, 2008

INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.

Related Content:

ArticlesGlaucoma

Applying cryopreserved amniotic membrane following intravitreal injection

Applying cryopreserved amniotic membrane following intravitreal injection

No ocular manifestations associated with inflammatory bowel disease, study finds

No ocular manifestations associated with inflammatory bowel disease, study finds

Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate

Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate